China: New Chinese Patent Law: What Does It Mean For Life Sciences Companies ?

After more than three years of preparation work, the revised PRC Patent Law ("New Patent Law") was finally promulgated on 27 December 2008 and will enter into force on 1 October 2009.

As a major emerging economy, China is striving to become an innovative country while facing major concerns such as accessibility to and affordability of medicines. The New Patent Law reflects this dilemma and thus the implementation difficulties are foreseeable

Changes to the patent regime that will mostly affect life sciences companies are genetic resources based patent, compulsory licence, parallel import and bolar exception. This article describes and comments these significant changes.

To view the article in full, please see below:

Full Article

After more than three years of preparation work, the revised PRC Patent Law ("New Patent Law") was finally promulgated on 27 December 2008. The New Patent Law will enter into force on 1 October 2009.

Changes to the patent regime that will mostly affect life sciences companies are genetic resources based patent, compulsory licence, parallel import and bolar exception.

Genetic resources

The New Patent Law has introduced for the first time a compliance requirement and a disclosure obligation for the application of patents based on genetic resources.

Firstly, Article 5 provides that no patent shall be granted if an invention is based on genetic resources obtained or used in violation of any laws or administrative regulations.

Where Article 27.2 of the TRIPS Agreement only provides that "Members may exclude from patentability inventions, the prevention within their territory of the commercial exploitation of which is necessary to protect ordre public or morality (...)", Article 5 sets out a general reference to "laws and regulations", which could seem to imply future more detailed laws and regulations on this matter.

Secondly, Article 26 of the New Patent Law requires the applicant to disclose and explain the direct and original source of the genetic resource. If the applicant is not able to disclose the original source, the applicant must provide the reasons.

This obligation is in line with and in advance of an international trend of introducing such disclosure obligations. For example, the Swiss patent law of 2008 includes such a disclosure obligation. In addition, 110 WTO members, including China, had proposed in the Doha negotiations in July 2008, to consider including a disclosure obligation in the TRIPS Agreement. The disclosure obligation is welcome at a same time for a better transparency in the access and benefit sharing of genetic resources, according to the Convention on Biological Diversity and the Bonn Guidelines on Access and Benefit Sharing. It is also believed that this disclosure obligation will improve the patent examiners' work.

However, Article 26 triggers many questions as to its implementation. How will the "direct source" and "original source" be defined? Which reasons would be acceptable for not disclosing the original source? Such questions may lead to implementation uncertainties and life sciences companies need to keep a close eye on them to ensure these requirements are complied with before they apply for a patent.

Compulsory licence

In addition to the circumstances of national emergency, extraordinary state of affairs, public interest or major technical progress of prominent economic significance based on a patent, which were already foreseen in the former patent law, the New Patent Law adds new grounds under which the Patent Office may grant a compulsory licence for patents.

Firstly, Article 48 provides that a compulsory licence may be granted when:

  • a patentee fails to exploit or fully exploit his patent without any justifiable reason within 3 years of the patent grant date or 4 years of the patent application date.
  • the patentee has been exploiting the patent rights in a monopolizing manner.

It is noted that the wording of Article 48 is vague which renders its application uncertain. At very least, definitions of "failure to exploit", "justifiable reason" or "monopolizing behavior" need to be provided to avoid any detrimental effects to patent holders.

Secondly, Article 50 provides that for reasons of public health policy, the Patent Office has the right to grant Chinese companies licences for patented medicines to be manufactured and exported to countries or regions with which the PRC has concluded related international treaties.

This provision implements the Decision of the Amendment of the TRIPS Agreement (2005) ratified by China on 28 November 2007, which reads that "the obligations of an exporting Member under Article 31(f) [according to which a compulsory licence shall only be granted for the supply of the domestic market of a Member] shall not apply with respect to the grant by it of a compulsory licence to the extent necessary for the purposes of production of a pharmaceutical product(s) and its export to an eligible importing Member(s) (...)".

Parallel import

The New Patent Law explicitly confirms that parallel import is not considered to be a patent infringement.

Article 69 of the New Patent Law provides that the use, offer for sale, sale and importation of patented products or products made from a patented method, which have been sold by the patent right holder or the entity or individual authorized by the patent right holder, shall not be considered as patent infringement.

Until the adoption of the New Patent Law, Chinese law did not contain such a provision. Without any legal basis, Chinese courts could inconsistently allow or condemn parallel import practices.

This provision provides clarification but is likely to further more affect the pricing of patented medicine made by foreign invested companies in China, because domestic companies have the right to import the products directly from another country where the price is more competitive.

Bolar exception

The Bolar exception has also been incorporated into the New Patent Law. Article 69 (5) provides that the manufacture, use and import of patented medicine or medical devices by someone other than the patent holder shall not be considered to be a patent infringement if such manufacture, use or import is solely for the purpose of obtaining administrative approval for the pharmaceuticals or medical device.

Unlike the EU Bolar exception clause, which literally limits the purpose of the Bolar exception to an abridged application process for generics, the Chinese Bolar exception may be applicable for new drugs.

Besides, it should be noted that China's drug approving authority, the SFDA, currently regulates that the applicant of a generic of a patented drug can only be accepted two years prior to the expiration of the patent. With this provision, the application of Bolar exception in China seems subject to a time limit.

The New Patent Law brings clarity to the former patent regime, but many terms which have been used remain to be defined.

As major emerging economies, China is striving to become an innovative country while facing major concerns such as accessibility to and affordability of medicines. The New Patent Law reflects this dilemma and thus the implementation difficulties are foreseeable.

This article was written for Law-Now, CMS Cameron McKenna's free online information service. To register for Law-Now, please go to

Law-Now information is for general purposes and guidance only. The information and opinions expressed in all Law-Now articles are not necessarily comprehensive and do not purport to give professional or legal advice. All Law-Now information relates to circumstances prevailing at the date of its original publication and may not have been updated to reflect subsequent developments.

The original publication date for this article was 11/03/2009.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions